التفاصيل البيبلوغرافية
| العنوان: |
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab |
| المؤلفون: |
Vallejo Vaz, Antonio Javier, Lawrence A. Leiter, Stefano del Prato, Marja-Riitta Taskinen, Dirk Müller-Wieland, Maja Bujas-Bobanovic, Alexia Letierce, Jonas Mandel, Rita Samuel, Kausik K. Ray |
| المساهمون: |
Universidad de Sevilla. Departamento de Medicina, Regeneron Pharmaceuticals, Inc., Sanofi |
| بيانات النشر: |
Oxford University Press |
| سنة النشر: |
2023 |
| المجموعة: |
idUS - Deposito de Investigación Universidad de Sevilla |
| مصطلحات موضوعية: |
Alirocumab, Goal attainment, Low-density lipoprotein cholesterol, Non-high-density lipoprotein cholesterol, Proprotein convertase subtilisin/kexin type 9, Triglycerides |
| الوصف: |
Aims: Guidelines recommend targeting non-high-density lipoprotein cholesterol to reduce cardiovascular risk. We assessed the impact of baseline triglycerides on non-high-density lipoprotein cholesterol goal attainment in 10 phase 3 trials with alirocumab versus control (n = 4983). Methods: Trials were grouped into four pools based on alirocumab dose (75-150 mg every 2 weeks), control (placebo/ezetimibe) and statin use. Baseline triglyceride quintiles were built within each pool. Non-high-density lipoprotein cholesterol goal attainment (very high risk: <100 mg/dl; moderate/high risk: <130 mg/dl), low-density lipoprotein cholesterol goal attainment (very high risk: <70 mg/dl; moderate/high risk: <100 mg/dl) and changes from baseline in lipid parameters were assessed at Week 24 among baseline triglyceride quintiles. Results: Higher baseline triglycerides were associated with a worse cardiovascular risk profile. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol increased with higher triglycerides, but the magnitude in non-high-density lipoprotein cholesterol was three- to four-fold higher compared with the increase in low-density lipoprotein cholesterol. Non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol percentage reductions from baseline with alirocumab were similar regardless of baseline triglycerides. A greater proportion of alirocumab-treated patients attained non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol goals compared with placebo or ezetimibe. Unlike low-density lipoprotein cholesterol goal attainment, non-high-density lipoprotein cholesterol goal attainment significantly declined with increasing baseline triglycerides (p < 0.05 for trend tests). A single standard deviation increase in baseline log(triglycerides) was significantly associated with lower odds ratios of attaining non-high-density lipoprotein cholesterol goals in the different pools and treatment (alirocumab/placebo/ezetimibe) groups, ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
European Journal of Preventive Cardiology, 27 (15), 1663-1674.; https://academic.oup.com/eurjpc/article/27/15/1663/5950574Test; https://idus.us.es/handle//11441/148044Test |
| الإتاحة: |
https://idus.us.es/handle//11441/148044Test |
| حقوق: |
Atribución-NoComercial 4.0 Internacional ; http://creativecommons.org/licenses/by-nc/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: |
edsbas.E8766A5C |
| قاعدة البيانات: |
BASE |
